{
  "guideline": {
    "id": "PA166262221",
    "name": "Annotation of CPIC Guideline for atorvastatin and SLCO1B1",
    "objCls": "Guideline Annotation",
    "source": "CPIC",
    "version": 5,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262221",
    "relatedChemicals": [
      {
        "id": "PA448500",
        "name": "atorvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297245",
      "name": "Recommendation PA166297245",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059847,
        "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "SLCO1B1": "Increased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297249",
      "name": "Recommendation PA166297249",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059851,
        "html": "<p>Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose &gt;20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk."
      ],
      "lookupKey": {
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297250",
      "name": "Recommendation PA166297250",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059852,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "SLCO1B1: n/a"
      ],
      "lookupKey": {
        "SLCO1B1": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297246",
      "name": "Recommendation PA166297246",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059848,
        "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
      },
      "implications": [
        "SLCO1B1: Typical myopathy risk and statin exposure"
      ],
      "lookupKey": {
        "SLCO1B1": "Normal Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297247",
      "name": "Recommendation PA166297247",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059849,
        "html": "<p>Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk"
      ],
      "lookupKey": {
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297248",
      "name": "Recommendation PA166297248",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA448500",
          "name": "atorvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059850,
        "html": "<p>Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose &gt;40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
      },
      "implications": [
        "SLCO1B1: Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk"
      ],
      "lookupKey": {
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
    }
  ],
  "version": "2024-03-08-14-34"
}